|
Hypertensive disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Mutations in the gene of WNK family, especially in WNK1 and WNK4 are responsible for pseudohypoaldosteronism type II (PHAII), characterized by hypertension.
|
31017050 |
2020 |
|
Hypertensive disease
|
0.500 |
AlteredExpression
|
group |
BEFREE |
We also found that WNK4 (its mutations lead to hypertension) expression, but not WNK1, was significantly increased in CLDN7<sup>-/-</sup> CD cell lines as well as in primary CLDN7<sup>-/-</sup> CD cells, suggesting that the expression of WNK4 was modulated by CLDN7.
|
31382627 |
2019 |
|
Hypertensive disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Variants of WNK1 (lysine deficient protein kinase 1), ADRB2 (β2 adrenergic receptor), NEDD4L (ubiquitin-protein ligase NEDD4-like), KLK1 (kallikrein 1) contribute to hypertension, and AKR1C3 (aldo-keto reductase family1 member C3), is associated with preeclampsia.
|
29777907 |
2018 |
|
Hypertensive disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The aim of this study was to investigate the association between With-No-Lysine (K) Kinase 1 (WNK1), Serine/Threonine kinase 39(STK39) genes variants and hypertension in the Tibetan population.
|
28945285 |
2018 |
|
Hypertensive disease
|
0.500 |
Biomarker
|
group |
BEFREE |
In the untreated hypertensive group, increased levels (<i>P</i><0.05) of the proinflammatory molecules p65 NF-κB, vascular cell adhesion molecule 1 and interleukin-6 antibody in the myocardium, aortic wall and PBMC were observed and were reduced with fasudil (<i>P</i><0.05).In conclusion, in this hypertension model, Rho-kinase and its pathway activation determined in circulating leukocytes reflect the activation of this pathway in the myocardium and in the aortic wall and are significantly related to myocardial remodeling (hypertrophy, fibrosis and inflammation).
|
30065083 |
2018 |
|
Hypertensive disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Mutations in the with-no-lysine kinase 1 (WNK1), WNK4, Kelch-like 3 (KLHL3), and Cullin3 (CUL3) genes were identified as being responsible for hereditary hypertensive disease pseudohypoaldosteronism type II (PHAII).
|
28414128 |
2017 |
|
Hypertensive disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Mutations in WNK1 and WNK4 are linked to a hereditary form of hypertension, and WNKs have been extensively investigated pertaining to their roles in renal epithelial ion homeostasis.
|
27131446 |
2016 |
|
Hypertensive disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Single nucleotide polymorphisms rs3754777 (STK39) and rs1468326 (WNK1) were associated with hypertension and BP in our multicenter Belgian case-control study, which supports the role of STK39 and WNK1 as potential hypertension susceptibility genes.
|
27082544 |
2016 |
|
Hypertensive disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Of those mRNAs, seven mRNAs in five genes (MME, PTPRO, REN, SLC12A3, and WNK1) had strong prior annotation to BP or hypertension.
|
25918036 |
2015 |
|
Hypertensive disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Consistent with previous reports, rs11064560 in WNK1 was also associated with bevacizumab-induced hypertension (OR 1.41 [95 % CI 1.04-1.92], P = 0.028).
|
24558090 |
2014 |
|
Hypertensive disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Mutations in the novel serine/threonine WNK [With No lysine (=K)] kinases WNK1 and WNK4 cause PHAII (pseudohypoaldosteronism type II or Gordon's syndrome), a rare monogenic syndrome which causes hypertension and hyperkalaemia on a background of a normal glomerular filtration rate.
|
23336180 |
2013 |
|
Hypertensive disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Common variations in the gene with no-lysine kinase 1 (WNK1) are associated with hypertension, but because of gene-environment interaction, it is difficult to fully identify the genetic contribution of WNK1 gene polymorphism to blood pressure (BP) variability.
|
23059770 |
2013 |
|
Hypertensive disease
|
0.500 |
AlteredExpression
|
group |
BEFREE |
The increased expression of L-WNK1 in the DCT results in increased activity of the Na-Cl cotransporter (NCC) and thus hypervolemia and hypertension.
|
22080857 |
2012 |
|
Hypertensive disease
|
0.500 |
Biomarker
|
group |
CTD_human |
Phosphatidylinositol 3-kinase/Akt signaling pathway activates the WNK-OSR1/SPAK-NCC phosphorylation cascade in hyperinsulinemic db/db mice.
|
22949526 |
2012 |
|
Hypertensive disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Our findings suggest that hypertension associated polymorphisms in WNK1 and WNK4 may not be predictors for antihypertensive response to diuretics.
|
21704025 |
2011 |
|
Hypertensive disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Hyperkalemic RTA accompanied by hypertension (pseudohypoaldosteronism type 2 [PHA2]) is caused by dominant gain-of-function mutations in the kinases WNK1 and WNK4.
|
21170890 |
2011 |
|
Hypertensive disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Mutations of WNK1 and WNK4 cause hypertension at least partly by increasing renal sodium retention.
|
18277144 |
2008 |
|
Hypertensive disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Loss of physiological regulation of the renal thiazide-sensitive Na+-Cl- cotransporter (NCC) by mutant WNK1 or WNK4 results in pseudohypoaldosteronism type II (PHAII) characterized by arterial hypertension and hyperkalemia.
|
18701621 |
2008 |
|
Hypertensive disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Recent studies indicated that SPAK and OSR1 are phosphorylated and activated by the WNK1 [with no K (lysine) protein kinase-1] and WNK4, genes mutated in humans affected by Gordon's hypertension syndrome.
|
16669787 |
2006 |
|
Hypertensive disease
|
0.500 |
Biomarker
|
group |
BEFREE |
The WNK1 and WNK4 protein kinases that are mutated in Gordon's hypertension syndrome phosphorylate and activate SPAK and OSR1 protein kinases.
|
16083423 |
2005 |
|
Hypertensive disease
|
0.500 |
AlteredExpression
|
group |
BEFREE |
This finding of association between a SNP near the promoter region and the severity of hypertension suggests that increased expression of WNK1 might contribute to BP variability and susceptibility to EH similar to the mechanism of hypertension observed in Gordon's syndrome.
|
15888480 |
2005 |
|
Hypertensive disease
|
0.500 |
Biomarker
|
group |
BEFREE |
WNK1: analysis of protein kinase structure, downstream targets, and potential roles in hypertension.
|
15686619 |
2005 |
|
Hypertensive disease
|
0.500 |
AlteredExpression
|
group |
LHGDN |
How overexpression of WNK1 leads to Na(+) retention and hypertension is not entirely clear.
|
15583131 |
2004 |
|
Hypertensive disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Recent evidence indicates that mutations in the gene encoding the WNK1 [with no K (lysine) protein kinase-1] results in an inherited hypertension syndrome called pseudohypoaldosteronism type II.
|
14611643 |
2004 |
|
Hypertensive disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Association of TSC and WNK1 with hypertension was not observed.
|
15309683 |
2004 |